Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Anglo American restructuring 'on track' as Q2 core output rises

(Sharecast News) - Anglo American has reported a "solid" second quarter, with its core businesses of iron ore and copper on track to meet full-year guidance, as the company continues to progress its massive restructuring plan. Copper output totalled 173,000 tonnes in the second quarter, down 11% over last year but 3% ahead of the first quarter, benefitting from strong performance at both the Quellaveco and Los Bronces projects, while Collahuasi improved from its first quarter.

Anglo also produced 15.9m tonnes of iron ore during the period, up 2% year-on-year and 3% over the quarter, with "another excellent quarter of delivery" from both the Minas-Rio and Kumba projects.

Meanwhile, output at the company's non-core businesses which it plans to exit - diamonds, steelmaking coal and nickel - were all significantly lower than comparative periods.

Chief executive Duncan Wanblad said the company's portfolio simplification and cost-reduction programmes remain "on track".

"Looking beyond this transitionary year, we will emerge as a highly differentiated, higher margin and more cash generative business setting us up to deliver the outstanding potential of our world class assets and resource endowments," Wanblad said.

Anglo shares were up 1% at 2,370p in early deals on Thursday.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.